CRISPR

In the late 1980s and mid-1990s, genomes of diverse lineages of bacteria and archaea (the latter representing a domain of single-celled prokaryotic microorganisms) revealed clusters of regularly interspaced short palindromic repeats, known today under the abbreviation CRISPR. Later it was found that these repeat sequences (previously considered disparate) share a common set of features.

CRISPR: Ethical and Safety Concerns

CRISPR and Cas proteins have become a crucial tool for genetic manipulation in biomedical research and biotechnology, and the crux of its action is the recognition of specific sequences in the DNA and their subsequent cleavage from the chain. One specific system, CRISPR-Cas9, has become the standard for genetic editing, since it can be tailored to target any set of DNA sequences. Thus it is of no wonder that it caused an upheaval in biomedical field.

What is CRISPR/Cas9?

CPISPR Applications

CRISPR: The End for Zinc Fingers?

How Does CRISPR Compare to Other Gene-Editing Techniques?

Could CRISPR Repair CFTR in Cystic Fibrosis Patients?

Manipulating RNA sequences using CRISPR-Cas13

CRISPR-Cpf1

CRISPR Interference (CRISPRi) for Gene Suppression

Electroporation and the Production of Knockout Mice

CRISPR-Cas14: Discovery, Function, Advantages

Uses of CRISPR/Cas Biosensing Systems

See more featured articles »

Editing Sperm DNA using CRISPR

Unlocking the Potential: CRISPR-Cas9 Gene Editing in Liver Diseases

Latest CRISPR News and Research

Advancing therapeutic insights: The impact of understanding cellular target engagement with NanoBRET® technology

In this Interview, NewsMedical speaks with Amy Landreman about NanoBRET® Technology and its role in cellular target engagement.

From Promega Corporation 30 May 2024

Innovative startups leading the charge in alternative proteins to solve global food crisis

A recent review in Nature Communications highlights the crucial role of innovative startups in advancing alternative protein sources to tackle global food security challenges and translate these efforts into commercial applications.

29 May 2024

Researchers decode spatial structure of prime editor

Joint research led by Yutaro Shuto, Ryoya Nakagawa, and Osamu Nureki of the University of Tokyo determined the spatial structure of various processes of a novel gene-editing tool called "prime editor."

29 May 2024

Changing the landscape of R&D to build clinical success from the ground up

In this interview, NewsMedical talks to Amanda Jones at Revvity about the strategies and solutions available to revolutionize the landscape of R&D in clinical research.

From Revvity 28 May 2024

Two new studies offer insights into the molecular biology of neuropsychiatric disease

Working under the umbrella of the PsychENCODE Consortium, the mental health research project established in 2015 by the National Institutes of Health, a team of Mount Sinai scientists has uncovered important new insights into the molecular biology of neuropsychiatric disease through two new studies published in a special issue of Science on Friday, May 24.

24 May 2024

New MOBE technology revolutionizes multiplexed genome editing

The human genome consists of around 3 billion base pairs and humans are all 99.6% identical in their genetic makeup.

21 May 2024

ERS Genomics and IRBM sign CRISPR/Cas9 license agreement

ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS’ CRISPR/Cas9 patent portfolio.

From ERS Genomics 21 May 2024

New CRISPR screen method reveals cellular drivers of neurological disorders

The brain is often referred to as a "black box"-;one that's difficult to peer inside and determine what's happening at any given moment.

20 May 2024

Repurposing human-approved drugs for prion disease treatment

Prions are the abnormal, pathogenic agents that are transmissible and are able to induce abnormal folding of specific normal cellular proteins.

16 May 2024

New study finds Sfrp1 as a potential therapeutic target in cancer treatment

Cancer is a leading cause of death globally. One of the primary reasons why cancer is such a deadly disease is the ability of cancer cells to become drug-resistant.

15 May 2024

Human cell-based model of thoracic aortic aneurysm offers new opportunities for drug development

Using human cells in laboratory rats, Michigan Medicine researchers have developed a functional model of thoracic aortic aneurysm, creating opportunities for more effective understanding of disease development and treatments for the potentially fatal condition, a study suggests.

14 May 2024

Scientists unlock mystery behind a deadly strain of cholera bacteria

A deadly strain of cholera bacteria that emerged in Indonesia back in 1961 continues to spread widely to this day, claiming thousands of lives around the world every year, sickening millions -; and, with its persistence, baffling scientists.

14 May 2024

ERS Genomics appoints John E Milad as Chief Executive Officer

ERS Genomics Limited (‘ERS’), the CRISPR licensing company, today announced the appointment of John E Milad as CEO, with immediate effect. John brings over 25 years of experience as an executive leader, venture capitalist, and investment banker focused on the life sciences and medical technology sectors.

From ERS Genomics 13 May 2024

New modular epigenome editing platform sheds light on gene regulation mechanisms

Understanding how genes are regulated at the molecular level is a central challenge in modern biology.

9 May 2024

Clinical trial shows CRISPR gene editing has exciting potential to treat a rare form of blindness

A recent study published in The New England Journal of Medicine investigated the potential use of gene editing to correct a congenital retinal degeneration called CEP290 that causes early-onset vision loss.

8 May 2024

Sapio Sciences Unveils Enhanced Molecular Biology Toolkit

...

From Sapio Sciences 7 May 2024

Rutgers scientists create CRISPR-edited mice to study the neurobiology of Tourette disorder

In research that may be a step forward toward finding personalized treatments for Tourette disorder, scientists at Rutgers University–New Brunswick have bred mice that exhibit some of the same behaviors and brain abnormalities seen in humans with the disorder.

6 May 2024

CRISPR-based gene editing shows promise in treating rare form of blindness

About 79% of clinical trial participants experienced measurable improvement after receiving experimental, CRISPR-based gene editing that is designed to fix a rare form of blindness, according to a paper published in the New England Journal of Medicine.

6 May 2024

MedStar Washington Hospital Center enrolls first U.S. patient in gene-editing therapy trial for heart disease

The first U.S. heart patient involved in a study for a new gene-editing therapy directly infused inside the body has successfully been enrolled at MedStar Washington Hospital Center.

6 May 2024

CRISPR gene editing shows promise for treating individuals with a form of inherited blindness

Results from a groundbreaking clinical trial of CRISPR gene editing in 14 individuals with a form of inherited blindness show that the treatment is safe and led to measurable improvements in 11 of the participants treated.

6 May 2024

CRISPR

Overview

What is CRISPR/Cas9?

CPISPR Applications

CRISPR: The End for Zinc Fingers?

Feature Articles

How Does CRISPR Compare to Other Gene-Editing Techniques?

Could CRISPR Repair CFTR in Cystic Fibrosis Patients?

Manipulating RNA sequences using CRISPR-Cas13

CRISPR-Cpf1

CRISPR Interference (CRISPRi) for Gene Suppression

Electroporation and the Production of Knockout Mice

CRISPR-Cas14: Discovery, Function, Advantages

Uses of CRISPR/Cas Biosensing Systems

Editing Sperm DNA using CRISPR

Unlocking the Potential: CRISPR-Cas9 Gene Editing in Liver Diseases

Latest CRISPR News and Research

Advancing therapeutic insights: The impact of understanding cellular target engagement with NanoBRET® technology

Innovative startups leading the charge in alternative proteins to solve global food crisis

Researchers decode spatial structure of prime editor

Changing the landscape of R&D to build clinical success from the ground up

Two new studies offer insights into the molecular biology of neuropsychiatric disease

New MOBE technology revolutionizes multiplexed genome editing

ERS Genomics and IRBM sign CRISPR/Cas9 license agreement

New CRISPR screen method reveals cellular drivers of neurological disorders

Repurposing human-approved drugs for prion disease treatment

New study finds Sfrp1 as a potential therapeutic target in cancer treatment

Human cell-based model of thoracic aortic aneurysm offers new opportunities for drug development

Scientists unlock mystery behind a deadly strain of cholera bacteria

ERS Genomics appoints John E Milad as Chief Executive Officer

New modular epigenome editing platform sheds light on gene regulation mechanisms

Clinical trial shows CRISPR gene editing has exciting potential to treat a rare form of blindness

Sapio Sciences Unveils Enhanced Molecular Biology Toolkit

Rutgers scientists create CRISPR-edited mice to study the neurobiology of Tourette disorder

CRISPR-based gene editing shows promise in treating rare form of blindness

MedStar Washington Hospital Center enrolls first U.S. patient in gene-editing therapy trial for heart disease

CRISPR gene editing shows promise for treating individuals with a form of inherited blindness

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up